FIELD: biologically active peptides. SUBSTANCE: invention relates to oligopeptides comprising amino acid sequence B-X-X-X-B-X-X-X-J-Tyr, in which: B represents Lys or Arg; X represents any amino acid other than a charged aliphatic amino acid or its D-isomer; and J represents Gly, Lys, or Arg; indicated amino acids being naturally occurring L isomers, their D-isomers, and norleucine, whereas indicated oligopeptide includes active part, which is other than (i) naturally occurring sequence of alpha-domain of antigen B of human leukocyte (HLA-B) 75-84, (ii) naturally occurring sequence of transmembrane sequence of alpha-chain of human T cell receptor, and (iii) sequence, which is mutant with respect either to (i) or to (ii) and has no more than two mutations. Invention also discloses: method of suppressing activation of lymphocyte cells, method of transplantation of animal donor organs or cells, method of inhibiting inflammatory citokin protein synthesis in cells, method of suppressing inflammatory reaction in mammals, method of modulating activity of hemecontaining enzyme, and method of retarding appearance of autoimmune disease in mammals. EFFECT: expanded possibilities of suppressing inflammatory diseases. 36 cl, 2 dwg, 2 tbl, 9 ex _
Title | Year | Author | Number |
---|---|---|---|
PD1-4-1BBL FUSION PROTEIN AND METHODS OF ITS USE | 2018 |
|
RU2769513C2 |
ANTIBODIES DIRECTED TO CD127 | 2015 |
|
RU2734076C2 |
THERAPEUTIC AGENTS | 2016 |
|
RU2747733C1 |
FUSED PROTEIN SIRPΑ-4-1BBL AND METHODS OF USING SAME | 2018 |
|
RU2769769C2 |
PEPTIDE OBTAINED FROM DEPDC1 AND VACCINE CONTAINING IT | 2016 |
|
RU2765574C2 |
ANTIBODIES AND POLYPEPTIDES AGAINST CD127 | 2017 |
|
RU2769352C2 |
COMPOSITIONS AND METHODS FOR DIAGNOSTICS AND TREATMENT OF TUMOUR | 2010 |
|
RU2563359C2 |
BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
FUSED MOLECULE CAPABLE OF INDUCING NON-INFLAMMATORY PHAGOCYTOSIS | 2022 |
|
RU2823919C1 |
IMMUNOMODULATING OLIGOPEPTIDES | 2007 |
|
RU2503684C2 |
Authors
Dates
2003-10-20—Published
1998-04-10—Filed